Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that capitalise on the natural biology of T cells to treat patients with solid tumours announced that in Phase II of its Phase I/II study TACTIC-2 (NCT04727151), which examines the safety and effectiveness of autologous TAC-T cell lead asset, TAC01-HER2, in targeting HER2 in relapsed or refractory gastric and gastroesophageal junction (GEJ) tumours, the first patient has been dosed, announced . TAC01-HER2 is a new cell treatment,that express a T-cell Antigen Coupler (TAC) that recognises the human epidermal growth factor receptor 2 (HER2), using genetically modified autologous T cells.
TACTIC-2 is an open-label, multicenter Phase I/II study that aims to establish safety, maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-HER2 as a monotherapy, and in combination with pembrolizumab, in subjects with HER2 positive gastric and gastroesophageal adenocarcinoma.
Triumvira Immunologics, is a leading clinical-stage solid tumor cell therapy company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company’s proprietary T cell Antigen Coupler (TAC) technology is a robust and versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies.
